FDA actions, compounding policy, enforcement and the rules shaping patient access.
A September 23 update describes plans to advance RP001v63 toward human testing. FDA records confirm an August designation, while clinical safety and benefit remain unestablished.
The September 25 decision adds an oral treatment for patients aged 12 and older with fibrodysplasia ossificans progressiva. A small randomized trial supports an effect on abnormal bone formation, while longer-term functional benefits remain unresolved.
The approval adds a lutetium Lu 177 dotatate option for adults with certain receptor-positive tumors. It builds on established treatment evidence without demonstrating superior outcomes over Lutathera.
The approval adds a weekly basal-insulin option backed by randomized trials showing comparable blood-sugar control to daily insulin. Fewer injections do not establish superior long-term health outcomes.
A newly published international consensus outlines standards for personalized treatment of difficult bacterial infections. Its practical recommendations do not establish broad clinical efficacy or confer regulatory approval.
The recommendation brings Zealand Pharma’s GLP-2 peptide therapy closer to European authorization. A randomized trial found reduced dependence on intravenous support, while final approval remains pending.
The September 18 decision adds an oral treatment option after endocrine therapy stops controlling advanced disease. Trial results support longer progression-free survival, while an overall-survival benefit remains unestablished.
The pharmaceutical supplier plans to expand peptide ingredients and technical services. The announcement follows an FDA alert involving a separate supplement-grade ingredient supplied by the company, underscoring the importance of intended use and manufacturing controls.
The new indication follows a trial showing reduced urinary albumin over six months. The labeling describes longer-term kidney protection as an expected benefit, preserving an important distinction between a biomarker result and clinical outcomes.
The program pairs drug developers with research institutions and introduces rolling review before a complete trial application. Whether it shortens development while preserving participant protection remains to be demonstrated.
Australian regulators reported finding undeclared semaglutide and no retatrutide in a product investigated after a hospitalization. The case highlights an ingredient-identity risk while leaving the frequency of such substitutions unknown.
Mimrylo reduced phlebotomy eligibility when added to existing care in a 293-person phase 3 trial. The approval establishes a new way to control excess red-cell production, although effects on thrombosis and survival remain unanswered.
The agency says at least 30 patients experienced adverse events after receiving compounded intravenous glutathione made with material labeled for dietary-supplement use. Two Texas pharmacies have recalled products after testing identified elevated bacterial endotoxin levels.
The Phase 3 ACACIA-HCM trial found modest improvements in symptoms and exercise capacity. Reduced ejection fraction and serious adverse events were more frequent with aficamten.
A peer-reviewed three-vial analysis found roughly half to nearly twice the labelled peptide content, while a laboratory’s larger surveillance summary also reported frequent mismatches. The limited, nonrandom samples raise quality concerns but cannot estimate the problem across the broader market.
The approval rests on a 241-person phase 3 trial in previously treated adults, where the higher tested dose improved a composite measure of muscle, skin and functional outcomes. Serious infections and the drug’s boxed warning remain important constraints on how the result should be interpreted.
The UK regulator said all NGPod handheld readers and sensors should be quarantined and discarded after the manufacturer ceased trading. An earlier safety action followed two reports in which the device indicated acidic conditions despite a nasogastric tube being in the lung, including one incident with a fatal outcome.
Vitestro’s Aletta can locate a vein and complete an adult outpatient blood draw under trained supervision. FDA authorization establishes a new device category, but evidence for staffing, access and workflow benefits remains limited.
A revised FDA import alert adds orforglipron products and spells out the evidence manufacturers may need to avoid detention. The action targets supply-chain quality, not the clinical effectiveness of GLP-1 medicines.
A new FDA discussion paper considers evaluating generative-AI medical devices through clinical benchmarks, real-world confirmation, and continuing surveillance. The proposal is an early request for feedback—not guidance or a change in regulatory requirements.
RegulationVitalspan Wire conceptual illustrationThe agency's new product-specific drafts sharpen the scientific path for evaluating complex peptide generics. Here is what changed—and what did not.
RegulationVitalspan Wire conceptual illustrationA practical guide to approval, quality review and the circumstances in which clinicians may turn to compounded medicine.